DNA Methylation Market

Global DNA Methylation Market is valued at USD 2063.9 Million in 2021 and expected to reach USD 5763.0 Million by 2028 with a CAGR of 15.8% over the forecast period.

 

Global DNA Methylation Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing demand for DNA methylation in metabolic diseases and oncology, and growing technological advancements are some of the major factors driving the growth of the Market.

Scope-

DNA methylation is the biological process by which methyl groups (-CH3) are added to a DNA molecule. Methylation can change the activity of the DNA segment without changing a sequence. When located in a gene promoter, DNA methylation normally acts to repress gene transcription. In mammals, DNA methylation is essential for normal development and is associated with many key processes, including genomic imprinting, X-chromosome inactivation, repression of transposable elements, carcinogenesis, and aging. Demethylation is a process that can be used to remove chemical groups. Generally, methylation turns genes "off," while demethylation "turns" genes "on".

The Covid-19 pandemic has also impacted the growth of the market. In the Covid-19 pandemic, reintroduction by academic and research institutions has increased the use of DNA methylation. In addition, the availability of a wide range of DNA methylation test kits through e-commerce channels has created further opportunities for market players. This has led to increased adoption of DNA methylation in academic institutions.

The global DNA methylation market is segmented on the basis of technology, application, end-use, product and region & country level. Based on technology, the market is segmented into high-resolution melt analysis, bisulfite DNA modification, methylated DNA immunoprecipitation, and others. By application, the market is segmented into oncology research, immunological assay, microarray, DNA sequencing, and others. By end-use, the global DNA methylation market is segmented into academic institutions, biotechnology industry, research laboratories, pharmaceutical industry, and others. By product, the global DNA methylation market is segmented into instruments & consumables, enzymes, reagents, kits, and others.

The regions covered in the global DNA methylation market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global DNA methylation is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc.

Key Players-

Some major key players for the global DNA methylation market report cover prominent players like -

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• F. Hoffmann-La Roche Ltd.
• Illumina Inc.
• Merck Group
• Pacific Biosciences of California Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Active Motif Inc.
• Diagenode Diagnostics SA
• EpiGentek Group Inc.
• New England Biolabs Inc.
• Zymo Research Corporation
• Abcam plc
• Exact Sciences Corporation
• others

Segmentation-

By Technology:

• High-Resolution Melt Analysis
• Bisulfite DNA Modification
• Methylated DNA Immunoprecipitation
• Others

By Application:

• Oncology Research
• Immunological Assay
• Microarray
• DNA Sequencing
• Others

By End-Use:

• Academic Institutions
• Biotechnology Industry
• Research Laboratories
• Pharmaceutical Industry
• Others

By Product:

• Instruments & Consumables
• Enzymes
• Reagents
• Kits
• Others

By Regional & Country Level:

• North America

• U.S.
• Canada

• Europe

• U.K.
• France
• Germany
• Italy

• Asia Pacific

• China
• Japan
• India
• Southeast Asia

• Latin America

• Brazil
• Mexico

• Middle East and Africa

• GCC
• Africa
• Rest of Middle East and Africa

Increasing Demand for DNA Methylation in Metabolic Diseases and Oncology, and Growing Technological Advancements are Some of the Major Factors Driving the Market Growth

One of the major factors driving the growth of the DNA methylation market is the increasing demand for DNA methylation in metabolic diseases, and oncology. Oncology is a field in which DNA methylation equipment is widely used to develop therapeutic strategies aimed at reversing the transcriptional abnormalities inherent in the cancer epigenome. This disruption of epigenetic changes, including DNA methylation and histone modifications, leads to alterations in gene function or expression as well as cellular transformation, leading to cancer. Hyper-methylation promotes cancer by repressing tumor suppressor genes. The absence of cancer-associated DNA methylation can alter transcription. New research shows that genomic 5-hydroxymethylcytosine is an intermediate in DNA de-methylation that leads to cancer-related damage. Furthermore, both decreased hydroxyl-methylation and DNA methylation play important roles in carcinogenesis. Because DNA derived from cancer cells is a stable molecule that can be easily detected in clinical samples such as blood, sputum, stool, and urine, DNA methylation changes in tumorigenesis have emerged as one of the promising candidate biomarkers for early detection, and the prognosis of cancer patients. Predicting therapeutic response, and monitoring recurrence. The field of DNA methylation biomarker research is rapidly evolving, with promising results that have the potential to provide enormous benefits to cancer patients in the future. And, according to World Health Organization, in 2020 cancer is the leading cause of death worldwide, with about 10 million deaths.

Moreover, the growing technological advancements are also supplementing the market growth. The demand for DNA methylation as an epigenetic biomarker in clinical laboratories to detect genomic disorders is increasing due to the increasing number of research activities conducted in recent times, which is expected to increase market revenue. DNA methylation is widely used in DNA sequencing as well as genomic analysis studies. This is expected to significantly increase the market revenue during the forecast period.

However, the high cost and low adoption associated with DNA methylation may hinder the growth of the global DNA methylation market. Despite that, the rising degree of funding for research and development in this field may create more opportunities for the further growth of the market.

North America is Expected to Dominate the Global DNA Methylation Market

Geographically, North America is expected to dominate the global DNA methylation market within the forecast period due to the increasing government funding for genomics research, rising incidence of cancer, and the growing availability of advanced infrastructure for genomic research in this region. Increasing government funding for genomics research is driving the growth of the market. For instance; on July 5^th, 2022; total spending on genomics research from 34 funding sources averaged $2.9 billion from 2003–2006. In addition, the rising incidences of cancer are also supplementing the market growth in this region. For instance; according to Division of Cancer Prevention and Control, Centers for Disease Control and Prevention; in the United States in 2019, 1,752,735 new cancer cases were reported and 599,589 people died of cancer. For every 100,000 people, 439 new cancer cases were reported and 146 people died of cancer.

The Asia Pacific is the fastest-growing region in the global DNA methylation market due to the increasing need for early diagnosis and treatment and rising incidences of cancer in this region. For example; according to an article published on Down to Earth; another study revealed that as many as 1,392,179 people were diagnosed with cancer in India in 2020. The researchers found that the five main sites of the disease were the breast, lungs, mouth, uterus, cervix, and tongue.

News-

DNA Methylation Start-Up Launched with $11m

On June 9^th, 2020; Base Genomics launched an $11m raise to commercialize epigenetic DNA methylation technology. Epigenetics company Base Genomics has emerged from stealth with a team of leading scientists and an oversubscribed seed funding round of $11 million USD (£9 million GBP) to advance its DNA methylation technology.

Oxford-Developed DNA Methylation Technology Formed a Basis of New Startup Company

On June 3^rd, 2020; Biotechnology company, Base Genomics, launched based on Dr. Chunxiao Song's innovative TAPS technology. TET-assisted pyridine borane sequencing is the new method for measuring DNA methylation, a chemical modification on cytosine bases. DNA methylation has an important regulatory role in the cell but is frequently altered in cancer.

Report Analysis	Details
Historical data	2018 - 2021
Forecast Period	2022 - 2028
Market Size in 2021:	USD 2063.9 Million
Base year considered	2021
Forecast Period CAGR %:	15.8%
Market Size Expected in 2028:	USD 5763.0 Million
Tables, Charts & Figures:	175
Pages	200
Companies	Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck Group, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Active Motif, Inc., Diagenode Diagnostics SA, EpiGentek Group Inc., New England Biolabs, Inc., Zymo Research Corporation, Abcam plc, Exact Sciences Corporation, and others
Segments Covered	By Technology, By Application, By Product, By End-Use
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa